Pfizer’s COVID-19 vaccine has been approved for use on residents aged five to 11 years after an advisory committee of the US Food and Drug Administration voted overwhelmingly in favor of inoculating young children. The vote of confidence came after the committee found that a low dosage provided more benefits than risks.
The expert panel’s advice will now go to the drug regulator for full approval before the recommendation is taken to the Centers for Disease Control, who will authorise the vaccine under emergency use.
